FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2531034485> ?p ?o ?g. }

• W2531034485 abstract "Abstract Abstract 4297 Background: In Tunisia children with acute lymphoblastic leukemia (ALL) are treated according to the EORTC 58951 protocol with complete remission rate (CR) of 84% and long-term survivals reaching 80% at 5 years. Survivals of adult ALL remain disappointing mainly because of the high rate of early deaths, the limited number of allografted patients performed only for those aged < 40y, and lack of access to the international bone marrow donors registry. Are the improvements made in the last decades in developed countries in the treatment of adult ALL transposable for patients diagnosed in developing countries? The aim of the present study is to report the experience of a Tunisian hematology center in the management of adult ALL. Patients and methods: Fifty one adult ALL patients were treated with three consecutive trials in the hematology department of Aziza Othmana university hospital of Tunis between January 2005 and July 2011.18 patients were treated with Tunisian LALA03 protocol (pediatric –inspired induction) between 2005 and 2007: BFM-like HR induction (PND 60mg/m2x22d, VCRx4, DNR 30mg/m2x4, ASPx8). HR patients receive 6 consolidations blocs (GRAALL03 blocs) + CNS RT+ maintenance therapy. SR patients receive EORTC AR2 consolidations (IB, interval therapy, IIAIIB) +CNS RT +maintenance therapy. This protocol led to an inacceptable rate of induction death of 38.8%. 24 and 9 patients were respectively treated with Hyper-CVAD regimen from 2008 to 2010 and GRAALL05 since 2010. Results: Male/female ratio was is 2.6. Median age was 37.5 years (21–59). Immunophenotyping revealed B-cell precursor and T-lineage ALL in respectively 60% and 35% of patients. 1 patient had biphenotypic leukemia and the immunophenotype was not precised in one case. Median baseline WBC count was 18.2 × 109/L (0.3–265 ×109/L). Three patients presented with central nervous system (CNS) disease at diagnosis. 21.5% of patients have Philadelphia positive ALL. Only 14 patients had SCT from a matched sibling donor. Complete remission rate after induction was 74.5%. Eight patients (15.6%) had early death during induction from septic shock and pneumonia in 5 and 3 cases respectively. Median overall survival (OS) was 18 months. 3 years OS was 30%. By univariate analysis, age less than 32 years (p=0.01) and bone marrow transplantation (p=0.04) had positive impact on OS. For the whole study population 3 year relapse free survival (RFS) was 20%. Despite a lower RFS with Hyper CVAD there was no significant difference between the three trials but a trend to better outcome with pediatric inspired trials i.e. LALA03 and GRAALL05. Conclusion: Pediatric-inspired protocols are associated with increased early death but prolonged remission duration compared to Hyper-CVAD. Hyper-CVAD is well tolerated but is associated to a high rate of relapse in our patients mainly because of the small number of SCT. The outcome of adult ALL in Tunisia is still unsatisfactory and can be improved with pediatric-like regimens. Effective therapy for adult ALL is feasible in our country. Controlling death induction by supportive measures and better management of myelosuppression and offering a stem cell transplant to a greater number of patients could be an option to improve on the RFS and OS. Disclosures: No relevant conflicts of interest to declare." @default.
• W2531034485 created "2016-10-21" @default.
• W2531034485 creator A5006061526 @default.
• W2531034485 creator A5018146438 @default.
• W2531034485 creator A5019341062 @default.
• W2531034485 creator A5020118455 @default.
• W2531034485 creator A5033849310 @default.
• W2531034485 creator A5041885795 @default.
• W2531034485 creator A5059261277 @default.
• W2531034485 creator A5063236502 @default.
• W2531034485 creator A5081326880 @default.
• W2531034485 creator A5082490388 @default.
• W2531034485 creator A5075587230 @default.
• W2531034485 date "2012-11-16" @default.
• W2531034485 modified "2023-10-17" @default.
• W2531034485 title "Adult ALL Patients Treated with Pediatric Inspired Trials Have Inacceptable Early Death but Better Relapse Free Survival Compared to Adult Trials: A Tunisian Single Center Experience" @default.
• W2531034485 doi "https://doi.org/10.1182/blood.v120.21.4297.4297" @default.
• W2531034485 hasPublicationYear "2012" @default.
• W2531034485 type Work @default.
• W2531034485 sameAs 2531034485 @default.
• W2531034485 citedByCount "0" @default.
• W2531034485 crossrefType "journal-article" @default.
• W2531034485 hasAuthorship W2531034485A5006061526 @default.
• W2531034485 hasAuthorship W2531034485A5018146438 @default.
• W2531034485 hasAuthorship W2531034485A5019341062 @default.
• W2531034485 hasAuthorship W2531034485A5020118455 @default.
• W2531034485 hasAuthorship W2531034485A5033849310 @default.
• W2531034485 hasAuthorship W2531034485A5041885795 @default.
• W2531034485 hasAuthorship W2531034485A5059261277 @default.
• W2531034485 hasAuthorship W2531034485A5063236502 @default.
• W2531034485 hasAuthorship W2531034485A5075587230 @default.
• W2531034485 hasAuthorship W2531034485A5081326880 @default.
• W2531034485 hasAuthorship W2531034485A5082490388 @default.
• W2531034485 hasConcept C126322002 @default.
• W2531034485 hasConcept C141071460 @default.
• W2531034485 hasConcept C147483822 @default.
• W2531034485 hasConcept C187212893 @default.
• W2531034485 hasConcept C194409129 @default.
• W2531034485 hasConcept C196166836 @default.
• W2531034485 hasConcept C203014093 @default.
• W2531034485 hasConcept C2780073493 @default.
• W2531034485 hasConcept C2781413609 @default.
• W2531034485 hasConcept C71924100 @default.
• W2531034485 hasConceptScore W2531034485C126322002 @default.
• W2531034485 hasConceptScore W2531034485C141071460 @default.
• W2531034485 hasConceptScore W2531034485C147483822 @default.
• W2531034485 hasConceptScore W2531034485C187212893 @default.
• W2531034485 hasConceptScore W2531034485C194409129 @default.
• W2531034485 hasConceptScore W2531034485C196166836 @default.
• W2531034485 hasConceptScore W2531034485C203014093 @default.
• W2531034485 hasConceptScore W2531034485C2780073493 @default.
• W2531034485 hasConceptScore W2531034485C2781413609 @default.
• W2531034485 hasConceptScore W2531034485C71924100 @default.
• W2531034485 hasLocation W25310344851 @default.
• W2531034485 hasOpenAccess W2531034485 @default.
• W2531034485 hasPrimaryLocation W25310344851 @default.
• W2531034485 hasRelatedWork W1936436543 @default.
• W2531034485 hasRelatedWork W1991253663 @default.
• W2531034485 hasRelatedWork W2020386488 @default.
• W2531034485 hasRelatedWork W2105379813 @default.
• W2531034485 hasRelatedWork W2241382955 @default.
• W2531034485 hasRelatedWork W2354155313 @default.
• W2531034485 hasRelatedWork W2521897773 @default.
• W2531034485 hasRelatedWork W2556675457 @default.
• W2531034485 hasRelatedWork W2558854175 @default.
• W2531034485 hasRelatedWork W2560147268 @default.
• W2531034485 hasRelatedWork W2588142421 @default.
• W2531034485 hasRelatedWork W2601668405 @default.
• W2531034485 hasRelatedWork W2733793042 @default.
• W2531034485 hasRelatedWork W2979318835 @default.
• W2531034485 hasRelatedWork W2979675959 @default.
• W2531034485 hasRelatedWork W2979796411 @default.
• W2531034485 hasRelatedWork W2987787412 @default.
• W2531034485 hasRelatedWork W3011299721 @default.
• W2531034485 hasRelatedWork W3095102021 @default.
• W2531034485 hasRelatedWork W80118321 @default.
• W2531034485 isParatext "false" @default.
• W2531034485 isRetracted "false" @default.
• W2531034485 magId "2531034485" @default.
• W2531034485 workType "article" @default.